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1. Introduction 
Osteoarthritis, a debilitating degenerative joint disease predominantly found in elderly 
individuals, has become the principal source of physical disability resulting in increased 
health care costs and impaired quality of life in the United States.  The pathogenesis of 
osteoarthritis (OA) involves the progressive deterioration of cartilage tissue, but many of the 
underlying biochemical and pathophysiological mechanisms involved in cartilage 
degradation and the induction of pain in this process remain largely unknown.  Recent 
literature has focused on understanding many of these processes, with the intention of 
developing novel therapies aimed at slowing and/or reversing cartilage degradation and 
inducing symptomatic relief.  This chapter provides an overview of several biochemical 
mediators involved in OA, with an emphasis on reviewing pertinent factors mediating 
cartilage breakdown and the induction of pain in degenerative conditions.   
2. Anatomy 
Articular cartilage lines the surfaces of joints and serves several important functions, 
including the provision of a smooth, low-friction surface, joint lubrication, and stress 
distribution with load bearing (1, 2).  The components of articular cartilage include an 
elaborate mixture of water (65-80% of wet weight), collagen (10-20% of wet weight), 
proteoglycans (PGs; 10-15% of wet weight), and chondrocytes (5% of wet weight) (1).   The 
extracellular matrix (ECM) includes collagen and PGs, principally aggrecan, with other 
proteins and glycoproteins in lesser amounts.  This matrix allows normal cartilage to form 
the resilient, low-friction surface capable of absorbing shock with high impact mechanical 
loading (3).   
Within the ECM, collagen fibers provide form, shape, and tensile strength to cartilage.  The 
principal collagen fibers present in articular cartilage are type II fibers, with smaller 
quantities of types V, VI, IX, X, and XI (1).  Collagen interacts to form fibrils that interact 
with and trap large aggregates of PGs, principally aggrecan.  PGs bind water and help 
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distribute stresses throughout the porous-permeable ECM under compressive loads.  
Aggrecan, the most abundant PG found in articular cartilage, is composed of a protein 
backbone bound by negatively-charged chondroitin sulfate and keratin sulfate groups.  It 
binds with hyaluronic acid (HA) to form complexes within the ECM.  Due to negatively-
charged sulfated groups, these complexes electrostatically interact with cations, ultimately 
forming ion-dipole interactions with water, allowing cartilage to function as a hydrated 
tissue that resists compression. 
The cellular makeup of cartilage consists of articular chondrocytes.  Chondrocytes maintain 
and produce the components of the ECM that regulate cartilage homeostasis.   They are 
mesenchymal in origin, few in number within the matrix, have a low rate of cell turnover, 
and receive nutrients and oxygen from the surrounding synovial fluid by means of diffusion 
(1).  Further, they respond to a variety of factors, including matrix proteins, mechanical load, 
and soluble mediators such as growth factors and cytokines.   
3. Metabolic disruption of cartilage homeostasis in osteoarthritis  
Under normal conditions, chondrocytes maintain a dynamic equilibrium between synthesis 
and degradation of ECM components.  In osteoarthritic states, however, there is a disruption 
of matrix equilibrium leading to progressive loss of cartilage tissue, clonal expansion of cells in 
the depleted regions, induction of oxidative states in a stressful cellular environment, and 
eventually, apoptosis of chondrocytes (2, 4).  With progression, there is usually an increase in 
both degradation and synthesis within the joint, with an overall shift toward catabolism over 
anabolism.  Chondrocyte metabolism is unbalanced due to excessive production of 
inflammatory cytokines and matrix-degrading enzymes, in conjunction with a downregulation 
of anabolic factors, eventually leading to destruction of the ECM and subsequent cartilage 
degradation.  Oxidative stress elicited by reactive oxygen species (ROS) further disturbs 
cartilage homeostasis and promotes catabolism via induction of cell death, breakdown of 
matrix components, upregulation of latent matrix-degrading enzyme production, inhibition of 
ECM synthesis, and oxidation of intracellular and extracellular molecules (2). 
One approach to slow or reverse catabolism involves attempts to downregulate the 
expression of catabolic factors and/or matrix-degrading enzymes, including matrix 
metalloproteases (MMPs) and a disintegrin-like and metalloprotease with thrombospondin 
motifs (ADAMTS family, aka aggrecanases)(5).   In particular, MMP-13 is the most potent 
collagen type II-degrading enzyme in human articular cartilage (6).  The regulation of 
matrix-degrading enzyme expression is stimulated by pro-inflammatory cytokines, growth 
factors, and metabolites, including lipopolysaccharide (LPS) (7), interleukin-1 (IL-1) (8), 
tumor necrosis factor-alpha (TNF-ǂ) (8), fibroblast growth factor-2 (FGF-2, otherwise known 
as basic FGF) (9), and ROS (10).  Equally important are attempts to upregulate anabolic 
factors in matrix homeostasis, including ECM components (e.g., aggrecan, collagen type II), 
growth factors (e.g. transforming growth factor (TGF)-ǃ, bone morphogenetic proteins 
(BMPs), and insulin-like growth factor-1 (IGF-1)), and/or anti-destructive enzymes [e.g., 
tissue inhibitor of metalloproteases (TIMPs)] to prevent cartilage degradation.   
4. Catabolic mediators in OA 
Healthy articular chondrocytes and synoviocytes constitutively synthesize and secret a wide 
array of mediators to maintain their delicate homeostasis. When inappropriately regulated, 
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a subset of mediators will drive detrimental catabolic processes in both cell populations, 
resulting in cartilage degeneration and chronic synovial inflammation. This section will 
summarize our current understanding of these key catabolic factors in OA pathogenesis. 
4.1 Inflammatory mediators 
Typical inflammatory mediators in OA include pro-inflammatory members from the 
interleukin family (IL-1, IL-6, and IL-17), TNF-ǂ, and prostaglandin E2 (PGE2). The roles of 
these mediators have been extensively studied in arthritic tissues secondary to their high 
concentrations in degenerative states. Each of these mediators not only stimulates the 
production of cartilage-degrading proteases, but also upregulates other destructive factors 
via paracrine or autocrine mechanisms, thus perpetuating disease progression. 
4.1.1 IL-1β 
IL-1ǃ is thought to play a prominent role in OA development.  It demonstrates potent 
bioactivities in inhibiting ECM synthesis and promoting cartilage breakdown.  Independent 
studies have shown that IL-1ǃ represses the expression of essential ECM components, 
aggrecan and collagen type II, in chondrocytes (11-13).  IL-1ǃ also strikingly induces a 
spectrum of proteolytic enzymes, including collagenases (MMP-1 and MMP-13) and 
ADAMTS-4, in both chondrocytes and synovial fibroblasts. Aside from these direct effects, 
IL-1ǃ induces a panel of cytokines, including IL-6, IL-8, and leukemia inducing factor (LIF), 
which produce additive or synergistic effects in the catabolic cascade (14).  Further, IL-1ǃ 
has been implicated in OA pathogenesis in numerous observational studies. Although less 
pronounced than what has been observed in rheumatoid arthritis patients, OA synovial 
fluids contains significantly higher levels of IL-1ǃ compared to normal synovial fluid (15). 
Immunohistochemical analyses also reveal increased expression of IL-1ǃ in OA cartilage 
and synovium (16, 17). Moreover, osteoarthritic chondrocytes exhibit heightened sensitivity 
to IL-1ǃ stimulation, in part due to augmented IL-1 receptor type I expression (18). This 
pathological change renders OA chondrocytes even more susceptible to deleterious IL-1ǃ 
attack. The significance of IL-1ǃ in OA was further corroborated by in vivo studies and 
pharmaceutical efforts using IL-1 receptor antagonist (IL-1ra) as a potential therapeutic 
factor to prevent cartilage degeneration. As an inhibitory molecule of IL-1ǃ, IL-1ra not only 
showed efficacy in OA animal models, but also improved clinical outcomes (19). 
4.1.2 IL-6 
Another constitutively expressed cytokine in human articular chondrocytes is IL-6 (20), yet 
only a fraction of OA patients contains increased IL-6 levels in arthritic cartilage and 
synovial fluid, suggesting that IL-6 may not be the ultimate driving force in this disease (21, 
22).  Nevertheless, in vitro studies demonstrate catabolic effects of IL-6 as this cytokine 
inhibits PG synthesis in chondrocytes, and this effect is potentiated by addition of soluble 
IL-6 receptor (sIL-6R) (23, 24).  Combination treatment with IL-6 and sIL-6R has been shown 
to enhance aggrecanase-mediated PG depletion in cartilage (25).  IL-6 also suppresses 
collagen type II expression (26), and to a lesser extent than IL-1ǃ, dysregulates enzymatic 
antioxidant defense mechanisms in chondrocytes via modulation of key enzymes (27). 
Therefore, it is surprising that male IL-6-/- mice displayed more severe OA phenotypes 
compared with wild-type mice (28). In this report, de Hooge et al suggest that IL-6 exerted 
joint protection in aging murine OA joints. However, their findings differ qualitatively from 
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those provided by Ryu et al, who reported that IL-6 promotes joint destruction in an 
instability-induced OA model (29). Further in vivo experiments are warranted to clarify such 
contradictions. Interestingly, a recent study suggested a mechanistic link between obesity 
and OA, based on the observation that the infrapatellar fat pad actively synthesizes IL-6 and 
sIL-6R in knee OA patients (30).  
4.1.3 IL-17 
The pro-inflammatory role of IL-17 is well-established in rheumatoid arthritis, but less so in 
OA. IL-17 is reported to exert stimulatory effects on MMP-3, MMP-13 and ADAMTS-4 
expression in chondrocytes (31, 32).  It directly inhibits PG synthesis, augments nitric oxide 
production, and triggers angiogenic factor release (33-35).  Further, the IL-17 response can 
be amplified dramatically when other destructive cytokines, such as IL-1ǃ and TNF-ǂ, are 
present. In chondrocytes, IL-17-mediated type II collagen breakdown and MMP expression 
is synergistically enhanced by IL-1, IL-6, or TNF-ǂ co-treatment (36).  Likewise, synergy in 
nitric oxide production was observed when chondrocytes were treated with IL-17 and TNF-
ǂ (37).  IL-17 also synergizes with IL-1ǃ or TNF-ǂ in PGE2 production in OA menisci ex vivo 
(38).  Cytokine induction serves as a secondary mechanism in IL-17-mediated effects. In 
chondrocytes and synovial fibroblasts, IL-17 induces certain pro-inflammatory cytokines 
and chemokines, such as IL-1ǃ, IL-6, and IL-8 (39, 40).  In macrophages, IL-17 effectively 
upregulates IL-1 and TNF-ǂ expression, which may contribute to chronic synovial 
inflammation observed in some OA patients (41). By way of adenovirus-mediated IL-17 
overexpression, Koenders et al. showed that IL-17 is capable of causing joint inflammation 
and bone erosion by itself, and also synergizes with TNF-ǂ (42). Conversely, IL-17 
deficiency markedly mitigates the arthritic phenotype in a collagen-induced arthritis model, 
but whether IL-17 ablation also provides similar protection in OA models awaits 
investigation (43). 
4.1.4 TNF-α 
The relevance of TNF-ǂ to OA pathogenesis is supported by the observation that TNF-ǂ 
receptor expression is significantly upregulated in OA cartilage (44, 45). TNF-ǂ 
concentration in synovial fluid also increases in patients with anterior cruciate ligament 
injury, suggesting this cytokine may play a role in OA development (46). Similar to IL-1ǃ, 
TNF-ǂ also promotes PG depletion (47-49). The induction of proteolytic enzymes MMP-3, 
MMP-9, and MMP-13 by TNF-ǂ in chondrocytes may account for such an action (50, 51). 
TNF-ǂ potently induces IL-6 and PGE2, which possibly results in secondary inflammatory 
events in the joint (47, 48, 52, 53). Another important process mediated by TNF-ǂ is cell 
death. It appears that excessive exposure to TNF-ǂ can elicit chondrocyte apoptosis, which 
will lead to local secondary necrosis and eventually a catabolic cascade due to absence of 
phagocytes in cartilage (54, 55). Consistent with these findings, TNF-ǂ transgenic mice 
exhibit spontaneous cartilage damage and conspicuous occurrence of arthritis (54). 
4.1.5 PGE2 
PGE2 is yet another significant player in chondrocyte metabolism. Upregulated in OA, 
PGE2 inhibits PG and type II collagen synthesis with the highest cellular sensitivity among 
all prostanoids produced by chondrocytes (56, 57).  Mechanistically, PGE2 appears to signal 
through the EP2 receptor to exert such inhibitory effects (58). Furthermore, EP4 receptor 
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activation increases MMP-13 and ADAMTS-5 expression, thus promoting ECM degradation 
(59). Interestingly, some evidence suggests that specific EP2 activation enhances cartilage 
regeneration in rabbit models, indicating species differences in PGE2 responses (60). PGE2 
also mediates or sensitizes chondrocytes to apoptosis (61, 62). Both IL-1 and TNF-ǂ induce 
PGE2 production, with the former being more potent (63-65), and the involvement of PGE2 
in IL-1ǃ-induced MMP-3 and MMP-13 expression is demonstrated in PGE synthase-1 
knockout chondrocytes. In these modified cells, the catabolic effects of IL-1ǃ are 
dramatically reduced (66). However, another group claims that PGE2 acts as a secretagogue 
of IGF-1, which in turn mediates anabolism in chondrocytes (67). Whether this induction 
brings any benefit to OA cartilage is questionable, because IGF-1 non-responsiveness has 
been reported in OA chondrocytes (68). 
4.2 Oxidative stress mediators, growth factors and glycoproteins 
4.2.1 Nitric oxide 
Nitric oxide (NO), a member of ROS, mediates the destructive actions of IL-1ǃ and TNF-ǂ in 
cartilage, including suppression of PG and collagen synthesis, as well as stimulation of 
MMPs (69-73). Spontaneous overproduction of NO produces similar effects in chondrocytes 
(73, 74), and prolonged exposure to NO together with other ROS can lead to apoptosis of 
articular cell types (62, 75, 76).  NO is also partially responsible for the insensitivity of OA 
chondrocytes to IGF-1 (77). As a mediator downstream of IL-1, NO also inhibits BMP-2-
mediated PG synthesis (78). 
Inducible nitric oxide synthase (iNOS) is the major enzyme responsible for NO generation in 
articular cartilage. OA chondrocytes in the superficial zone express higher levels of iNOS 
(79, 80).  Several destructive cytokines, including IL-1 and TNF-ǂ, induce iNOS expression 
in articular cell types (81, 82). Forced expression of iNOS inhibits matrix synthesis in 
chondrocytes (74).  Futher, in OA cartilage, iNOS inhibition gives rise to IL-10 induction and 
MMP-10 repression in the presence of IL-1ǃ (83). More recently, iNOS was found to function 
as a crucial mediator downstream of the advanced glycation end products pathway and the 
leptin pathway in chondrocytes (84, 85). Pelletier et al provided compelling evidence 
regarding the importance of iNOS in OA progression. In their canine OA model, selective 
inhibition of iNOS resulted in marked attenuation of joint destruction (86). Intra-articular 
delivery of an iNOS inhibitor counteracts the acute effects mediated by IL-1ǃ, reaffirming 
the catabolic role of iNOS in OA progression (87). 
4.2.2 FGF-2 
A series of studies have demonstrated that FGF-2 (otherwise known as basic FGF) acts as a 
catabolic growth factor in addition to its well-established mitogenic role in articular 
cartilage. Despite its positive effect on proliferation, FGF-2 inhibits IGF-1/BMP-7-enhanced 
PG deposition in human articular chondrocytes, and negatively affects the physical 
properties of normal cartilage (88, 89). FGF-2 alters the ratio of type II to type I collagen in 
articular chondrocytes, thus possibly leading to the formation of fibrocartilage, a poor 
substitute for hyaline cartilage (90, 91). In porcine chondrocytes, FGF-2 antagonizes IGF-
1/TGF-ǃ-mediated decorin and type II collagen production (92). Moreover, FGF-2 promotes 
cartilage degeneration ex vivo (93). A mechanistic explanation of FGF-2-mediated effects lies 
in its ability to upregulate MMP-13 and ADAMTS-5 (94, 95). FGF-2 orchestrates the MAPK, 
NFκB, and substance P signaling pathway to induce MMP-13 (5, 93, 94). It has also been 
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shown that activation of FGF receptor 1 (FGFR1) is required for FGF-2-mediated MMP-13 
and ADAMTS-5 induction (95).  
Results acquired from comparative analyses suggest the biological relevance of FGF-2 to 
OA. FGF-2 levels in OA synovial fluids are significantly elevated compared to those in 
normal specimens (94). FGFR3 expression is markedly diminished in OA chondrocytes, 
which results in altered FGFR1 to FGFR3 ratios and may account for the inhibition of 
anabolism in the disease state (95). It should be noted that other studies indicate a 
chondroprotective role of FGF-2 in cartilage biology (96, 97). The discrepancies may arise 
from differences in cell origin (i.e. species, age, severity of OA, etc), and render future 
clarifications necessary. 
4.2.3 Fibronectin 
Fibronectin (Fn) is an adhesive glycoprotein found in cartilage and synovial membrane 
tissue (98). Evidence shows that Fn level is increased in OA cartilage as well as OA synovial 
fluid (99, 100). Heightened proteolytic activities in OA joints lead to the generation of Fn 
fragments (Fn-fs) of different sizes. Specifically, ADAMTS-8 was characterized as a 
fibronectinase in OA chondrocytes (101). Indeed, Fn-fs are found with increased abundance 
in OA synovial fluids and cartilage (99, 102). A 40-kDa collagen-binding Fn-f induces 
sustained PG degradation in both normal and OA cartilage (103). Furthermore, Fn-f 
stimulates type II collagen cleavage in an MMP-13-dependent manner (104). Preceding 
collagen disintegration, Fn-f disrupts the ECM by promoting the release of cartilage 
oligomeric matrix protein (COMP) and chondroadherin (105). Fn-f also augments cytokine, 
ROS, MMP and aggrecanase production in cartilage ex vivo and in vitro (10, 106-109). 
Stimulation of IL-1 leads to enhanced production of Fn-f, which exerts prolonged 
destructive effects (99). 
4.2.4 Osteopontin 
Osteopontin, a phosphorylated glycoprotein with cell and matrix binding affinities, has 
been characterized as a facilitator of osteoclast adhesion and an initiator of osteoid 
mineralization (110). Osteopontin deposition in cartilage exhibits a spatial pattern, based on 
the fact that it is mainly detected in chondrocytes residing in the upper deep zone (111). 
Comparative analyses reveal that, in contrast with healthy chondrocytes, OA chondrocytes 
express notable levels of osteopontin (111). Moreover, an apparent correlation exists 
between osteopontin level and the severity of OA lesions (111-113).  
Nevertheless, the role of osteopontin in cartilage remains controversial. Osteopontin 
promotes calcium pyrophosphate dehydrate (CPPD) crystal formation in articular 
cartilage, suggesting that elevated osteopontin production in OA may be detrimental 
(114). Yet this stimulatory effect seems to depend on osteopontin concentration, because 
other studies demonstrate the opposite using higher concentrations of this protein (115). 
Another independent study also showed that osteopontin inhibits IL-1ǃ-induced NO and 
PGE2 production in OA cartilage, suggesting an anti-catabolic role in cartilage 
homeostasis (116). Osteopontin deficiency exacerbates aging-induced and instability-
induced OA in mice (117). Based on these apparently contradictory activities, it raises the 
possibility that osteopontin elicits different biological effects depending on the stages of 
OA. 
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4.2.5 Osteonectin 
Osteonectin is a non-collagenous glycoprotein linking collagen fibrils to mineral in bone. It 
is also present in mineralizing chondroid bone (118). Articular chondrocytes synthesize 
osteonectin, and this process is regulated by endogenous stimuli. IL-1, TNF-ǂ, and FGF-2, 
but not IL-6, greatly inhibit osteonectin expression (119, 120). IL-1 also impairs the 
glycosylation of osteonectin (120). On the other hand, TGF-ǃ, PDGF, and IGF-1 upregulate 
osteonectin synthesis, even in the presence of IL-1 (119, 120). Osteonectin is localized to the 
superficial and middle zones of OA cartilage, while normal cartilage does not display such a 
pattern (120, 121). Osteonectin synthesis is also enhanced in OA synovial fibroblasts (120). 
Osteonectin induces collagenase expression in this cell type, which may contribute to 
cartilage damage (122). 
4.3 Protective mediators in OA 
In contrast to the aforementioned catabolic mediators in OA, several growth factors take on 
important anabolic roles in the joint, thus serving as potential targets for future therapeutic 
growth factor therapy in practice.  While the literature has only begun to explore the in vitro, 
in vivo, and clinical effects of many of these factors, there is potential for these mediators to 
be major players in the treatment of degenerative joint diseases in the future.  Multiple 
cytokines exert protection in articular joints, including IL-1 receptor antagonist (IL-1ra), IL-4, 
IL-10, IL-11, and IL-13. Perhaps the most well-studied anabolic factors to date include TGF-
ǃ, BMP-2, BMP-7, and IGF-1 (Table 1).  We will also discuss two factors elucidated in our 
laboratory to have potent anabolic and anti-catabolic effects in human articular cartilage: 
resveratrol (RSV) and bovine lactoferricin (LfcinB).   
4.3.1 Interleukins 
The antagonistic effect of IL-1ra on IL-1 has been well established. By directly competing 
against IL-1 for its cognate receptor, IL-1ra effectively inhibits IL-1-mediated responses in 
chondrocytes, including PG depletion, MMP induction, and cytokine induction (123-125). 
IL-1ra expression is repressed by NO, which may blunt its action in OA cartilage (126). Not 
surprisingly, forced expression of IL-1ra confers resistance to IL-1 challenge in chondrocytes 
(127, 128). Both gene delivery and IL-1ra intra-articular injection have been shown to 
impede OA progression, indicating anti-IL-1 therapy is a viable option in OA disease 
modification (19, 129). 
Protective roles of anti-inflammatory cytokines have also been linked to OA. An array of 
cytokines, including IL-4, IL-10, IL-11, and IL-13, has been shown to block the actions of 
catabolic cytokines via different mechanisms.  IL-4 suppresses MMP-13, cathepsin B, and 
iNOS when cyclic tensile stress is applied on chondrocytes (130, 131).  IL-4 has potent 
inhibitory effects on cartilage degradation in the presence of IL-1 and TNF-ǂ (132). In 
synoviocytes, IL-4 downregulates apoptosis (133). IL-4 gene therapy appears to dampen 
inflammation in chondrocytes (134). Moreover, intra-articular injection of IL-4 results in 
notable amelioration of cartilage degenerative status (131). 
IL-10 is upregulated in OA chondrocytes, and this phenomenon may represent a reparative 
effort (135). IL-10 suppresses IL-1 and TNF-ǂ production (136). Compared to IL-1ra, IL-10 
gene delivery into synoviocytes elicits moderate yet still significant protection on cartilage 
(137). 
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IL-1┚ -: ↓ PG synthesis; ↓ type II collagen synthesis; ↑ MMPs; ↑ ADAMTS-4; ↑ 
ROS; ↑ IL-6; ↑ IL-8; ↑ LIF; ↑ synovial inflammation
IL-6 
-: ↓ PG synthesis; ↓ type II collagen synthesis; ↑ PG depletion; 
dysregulation of antioxidant defense
IL-17 
-: ↓ PG synthesis; ↑ type II collagen breakdown; ↑ MMPs; ↑ ADAMTS-4; ↑ 
NO; ↑ IL-1ǃ; ↑ IL-6; ↑ IL-8; ↑ PGE2 (in menisci); ↑ TNF-ǂ (in macrophage) 
TNF-┙ -: ↑ PG depletion; ↑ MMPs; ↑ IL-6; ↑ PGE2; ↑ chondrocyte apoptosis 
PGE2 
-: ↓ PG synthesis; ↓ type II collagen synthesis; ↑ MMPs; ↑ ADAMTS-5; ↑ 
chondrocyte apoptosis
NO 
-: ↓ PG synthesis; ↓ type II collagen synthesis; ↑ MMPs; ↓ IGF-1 sensitivity; 
↑ apoptosis
FGF-2 
-: ↓ PG deposition; ↓ ratio of type II to type I collagen; ↑ MMP-13; ↑ 
ADAMTS-5
Fn-f 
-: ↑ PG degradation; ↑ type II collagen cleavage; ↑ COMP and 
chondroadherin release; ↑ MMPs; ↑ aggrecanases; ↑ destructive cytokines 
Osteopontin 
-: ↑ CPPD formation
+: ↓ NO; ↓ PGE2 (concentration-dependent) 
Osteonectin -: ↑ collagenases (in synovial fibroblasts)
(-) = Catabolic effects; (+) = Anabolic or anti-catabolic effects 
Table 1. Effects of  Catabolic Mediators in Articular Cartilage 
 
IL-1ra +: ↓ IL-1-mediated responses
IL-4 
+: ↓ MMP-13; ↓ cathepsin B; ↓ iNOS; ↓ synovial fibroblast apoptosis; ↓ IL-
1/TNF-ǂ-mediated cartilage degradation
IL-10 +: ↓ IL-1; ↓ TNF-ǂ; ↑ cartilage protection
IL-11 
+: ↑ TIMP-1; ↓ pro-inflammatory cytokines; ↓ NO; ↓ TNF-ǂ responses 
(synovial fibroblast)
IL-13 
+: ↓ MMPs; ↓ IL-1ǃ; ↓ TNF-ǂ; ↑ IL-1ra; ↓ PGE2 and COX-2 (synovial 
fibroblasts); ↓ synoviocyte apoptosis
TGF-┚  +: ↑ chondrocyte activity, ↑ PG synthesis, ↑ ECM synthesis; ↓IL-1,  ↓ROS 
- : Osteophyte formation and synovial inflammation with prolonged exposure 
BMP-2 
+: ↑ ECM synthesis, ↑ collagen II expression
- :  +/- aggrecan degradation?
BMP-7 
+: ↑ chondrocyte activity, ↑ PG synthesis, ↑ ECM synthesis; ↓cell proliferation; 
age-independent, ↑activity of other anabolic factors (IGF-1, BMPs), ↓MMPs, 
↓IL-1 and IL-6; ↑ cartilage repair in vivo (sheep, rabbits) 
- :  Unknown
IGF-1 
+: ↑ ECM synthesis, ↑ PG synthesis; ↓apoptosis; + synergism with BMP-7 
- :  ↓effect with ↑ age and on OA cartilage
RSV 
+: ↑ ECM synthesis, ↑ PG (aggrecan) synthesis; ↑ collagen II expression; ↓IL-1  
& FGF-2 effects,   + synergism with BMP-7 
- : preliminary data; no in vivo studies
LfcinB 
+: ↑ ECM synthesis, ↑ PG (aggrecan) synthesis; ↑ collagen II expression; ↓IL-1 
& FGF-2 effects ,   + synergism with BMP-7 
- :  preliminary data; no in vivo studies
Table 2. Effects of Protective Mediators in Articular Cartilage 
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IL-11, an IL-6 family member, is believed to exert anti-catabolic and anti-inflammatory 
effects in articular joints, but remains poorly defined. IL-11 produced by articular 
chondrocytes stimulates the production of tissue inhibitor of metalloproteinase (TIMP) 
(138). IL-11 also downregulates pro-inflammatory cytokines and NO production (139). In 
OA synovial fibroblasts, IL-11 alone had no impact on PGE2 release, but shows anti-
inflammatory properties in conjunction with TNF-ǂ (140). In RA synovium, IL-11 directly 
inhibits MMP-1 and MMP-3 production, upregulates TIMP-1, and inhibits TNF-ǂ 
production in the presence of soluble IL-11 receptor (141). Importantly, systemic treatment 
with IL-11 leads to a significant reduction in clinical and histological severity of established 
collagen-induced arthritis (CIA), suggesting an active role of IL-11 in joint homeostasis 
(142). IL-11 level is greatly increased in OA synovial fluid (143). However, IL-11 action is 
likely to be blunted due to the observation that the IL-11 receptor is markedly 
downregulated in OA chondrocytes  (Im et al., unpublished data). 
IL-13 downregulates MMP-13 expression in OA chondrocytes (144). Combined with IL-4, IL-
13 abolishes IL-17 expression in RA synovial tissue (145). A more detailed study revealed that 
IL-13 represses IL-1ǃ, TNF-ǂ, and MMP-3, and simultaneously induces IL-1ra (146). IL-13, as 
well as IL-4 and IL-10, reduces TNF-ǂ-induced PGE2 release and cyclooxygenase 2 (COX-2) in 
OA synovial fibroblasts (147). Similar to IL-4, IL-13 also inhibits synoviocyte apoptotic events 
(133). Nonetheless, IL-13 levels were found to be low in OA tissues (148). Whether IL-13 holds 
significance to OA pathogenesis needs to be further determined, especially in animal models. 
4.3.2 TGF-/BMP Superfamily 
The TGF-ǃ superfamily is composed of over 35 structurally-related members, with the 
majority of these members playing fundamental roles in development and homeostasis.  In 
articular cartilage, three members of the TGF-ǃ superfamily have been shown to play a 
significant role in cartilage homeostasis: TGF-ǃ, BMP-2, and BMP-7.  BMPs are structurally 
related to the transforming growth factor-ǃ (TGF-ǃ) superfamily and have wide-ranging 
biological activities, including the regulation of cellular proliferation, apoptosis, 
differentiation and migration, embryonic development and the maintenance of tissue 
homeostasis during adult life (149-151).  It is now clear that they are expressed in a variety 
of tissues including adult articular cartilage. 
4.3.2.1 TGF- 
Several studies demonstrate an anabolic role of TGF-β in articular cartilage. TGF-β has been 
shown to upregulate chondrocyte synthetic activity and suppress the catabolic activity of IL-
1 (152, 153).  In vitro, TGF-β stimulates chondrogenesis of synovial lining and bone marrow-
derived mesenchymal stem cells (154).  Additionally, asporin inhibits TGF-ǃ-mediated 
stimulation of cartilage matrix genes such as collagen type II and aggrecan, and inhibits 
accumulation of PGs (155).  In both Japanese (155) and Han Chinese (156) populations, 
patients with an asporin polymorphism demonstrated increased prevelance of arthritic 
conditions, presumably via inhibition of TGF-β expression, suggesting a protective role of 
TGF-β in articular cartilage.  These findings were corroborated in knockout mice, as mice 
deficient for TGF-β or Smad3 (downstream mediator of TGF-β) developed cartilage 
degeneration resembling human OA (157, 158).  Other studies demonstrate a vital role of 
TGF-β in the suppression of NO and other ROS levels (159), as well as the upregulation of 
PG synthesis in calf-cartilage explants in a dose-dependent manner (152, 160).   
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However, the literature also suggests that TGF-β demonstrates nondesirable side effects in 
joint tissues.  For example, upon sustained exposure to in the joint, TGF-β can actually 
induce the formation of OA-like tissue pathology via stimulation of osteophyte formation, 
stimulation of synovial inflammation and fibrosis, and attraction of inflammatory 
leukocytes to the synovial lining (152, 153, 161, 162).  These  contradictory findings warrant 
further investigation, and recent research efforts are focused on downstream receptor usage 
to help provide further clues (152).  Nevertheless, given its deleterious effects not seen in 
other growth factor-based strategies, TGF-ǃ therapy is not presently a viable option for use 
in articular cartilage repair or regeneration.   
4.3.2.2 BMP-2 
Several studies have analyzed the role of BMP-2 in cartilage and found promising results.  
The effect of BMP-2 on mesenchymal stem cells is similar to that of TGF-ǃ, with increased 
production of ECM and decreased expression of collage type 1, theoretically suppressing the 
formation of fibrocartilage (149, 154).  In vitro analysis reveals that BMP-2 stimulates matrix 
synthesis and reverses chondrocyte dedifferentiation as indicated by an increase in synthesis 
of cartilage-specific collagen type II in OA chondrocytes (163).  In rabbit knees, BMP-2-
impregnated collagen sponges implanted into full-thickness cartilage defects enhance 
cartilage repair compared with empty defects or defects filled with collagen sponge alone, 
with this effect remaining at one year after implantation (164).  Interestingly, however, in an 
IL-1-induced cartilage degeneration model in mice, BMP-2 stimulated matrix production via 
increased collagen type II and aggrecan expression (anabolic activity), but also increased 
aggrecan degradation as well, revealing a possible catabolic or self-regulatory role (165).  
Further studies are indeed warranted to further elucidate the effects of BMP-2 on cartilage 
repair.   
4.3.2.3 BMP-7 
BMP-7 (also known as osteogenic protein-1), another member of the TGF-ǃ superfamily, is 
perhaps the most well-studied anabolic growth factor in cartilage repair.  It is expressed in 
cartilage and exerts potent anabolic effects by stimulating differentiation and metabolic 
functions of both osteocytes and chondrocytes (166).  In bone, a variety of animal models 
have clearly demonstrated a therapeutic potential of BMP-7 in bone repair applications, 
paving the way for BMP-7 to be used as the first commercial BMP to be used for bone repair 
clinically (149).  In articular cartilage, BMP-7 has potent anabolic effects by stimulating 
matrix biosynthesis in both human adult articular chondrocytes (167) and human IVD cells 
(168).   
In vitro, BMP-7 has several anabolic and anti-catabolic effects on articular cartilage.  It 
promotes cell survival and upregulates chondrocyte metabolism (169) and protein synthesis 
without creating uncontrolled cell proliferation and formation of osteophytes, unlike other 
chondrogenic growth factors  (149, 151). In a comparison study examining BMP-2, -4, -6, and 
-7, as well as cartilage-derived morphogenetic protein (CDMP)-1 (also known as GDF-5, 
growth differentiation factor-5) and CDMP-2, PG synthesis was stimulated to a greater 
extent by BMP-2 and -4, and the most significant upregulation after stimulation with BMP-7 
(150).  Importantly, its actions in cartilage are age-independent as BMP-7 induced similar 
anabolic responses in normal and OA chondrocytes from both young and old donors 
without inducing chondrocyte hypertrophy or changes in phenotype (151, 170, 171).   
Chubinskaya and colleagues have revealed that the anabolic effect of BMP-7 extends beyond 
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stimulation of cartilage ECM proteins and their receptors, but also modulates the expression 
of various anabolic growth factors as well (IGF-1, TGF-ǃ/BMPs) (151).  In addition to its 
anabolic capacity, BMP-7 effectively counteracts chondrocyte catabolism, revealing a potent 
anti-catabolic effect in human articular cartilage.  BMP-7 inhibits the expression of pro-
inflammatory cytokines (IL-1 and IL-6), inhibits endogenous expression of cytokines (ie. IL-
6, IL-8, IL-11) and their downstream signaling molecules (receptors, transcription factors, 
and mitogen-activated kinases), and blocks both a baseline and cytokine-induced expression 
of MMP-1 and MMP-13 (151).  BMP-7 has also been shown to enhance the gene expression 
of the anabolic molecule tissue inhibitor of metalloproteinase (TIMP) in normal and OA 
chondrocytes (151), and acts synergistically with the anabolic growth actors IGF-1 (169) and 
TGF-ǃ (172). 
Data from animal studies reveal that BMP-7 clearly has therapeutic potential for cartilage 
repair.   In a large chondral defect study in sheep cartilage, BMP-7 was shown to induce 
significant cartilage repair in a model where no repair takes place in the controls (173).  
Studies evaluating models of OA, however, are less numerous, but BMP-7 has been shown 
to prevent development of damage and in some models reverse the damage (151).  Finally, 
although BMP-7 is highly effective at stimulating bone repair, it does not appear to lead to 
osteophyte formation when administered into a joint, nor does it stimulate uncontrolled 
fibroblast proliferation (leading to fibrosis) (149).  Studies have demonstrated that 
recombinant BMP-7 use has a relatively safe profile with few side effects in rabbits, dogs, 
goats and sheep.  Overall, the data clearly indicate that BMP-7 has an important role in 
cartilage, both in normal homeostasis and in repair, but several unknowns continue to exist, 
such as concentration, dosing, the use of scaffolds, methods of administration, and possibly 
combinations with other factors.  
4.3.3 IGF-1 
IGF-1 is a single chain polypeptide that is structurally similar to insulin, a key growth factor 
that enhances PG synthesis in articular cartilage (174).  Much like BMP-7, IGF-1 has a 
promising future in the field of cartilage repair and regeneration therapy.  In vitro, IGF-1 
induces anabolic and anti-catabolic effects in normal articular cartilage from a variety of 
species (53, 175).  In vivo studies support in vitro findings, as IGF-1 deficiency in rats leads to 
the development of articular cartilage lesions (176).  In animal models, IGF-1 enhances 
repair of extensive cartilage defects and protects synovial membrane tissue from chronic 
inflammation (177, 178).  Other studies in spine cartilage demonstrate similar results.  Osada 
et al showed that IGF-1 stimulates PG synthesis in bovine NP cells in serum-free conditions 
in a dose-dependent manner and proposed an autocrine/paracrine mechanism of action 
(179).  Gruber and colleagues found that the addition of IGF-1 increased cell survival upon 
experimental induction of apoptosis in spine disc annulus fibrosus cells (180), consistent 
with the anti-catabolic capacity of IGF-1 in both intervertebral disc (IVD) and articular 
cartilage tissues. 
Despite its potent anabolic and anti-catabolic effects on normal cartilage tissue, however, 
IGF-1 appears to have a diminished ability to stimulate ECM formation and decrease 
catabolism with both age (181, 182) and OA (68, 149, 181).  There appears to be an 
uncoupling of IGF-1 responsiveness in OA, as IGF-1 is able to stimulate matrix synthesis but 
is unable to decrease matrix catabolism (183).  Nevertheless, combination growth factor 
therapy with IGF-1 and BMP-7 results in greater repair potential than either factor alone 
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(169), and the effects of combination factor therapy on aged and old cartilage defects have 
yet to be determined.   
4.3.4 Resveratrol 
The phytoestrogen resveratrol (trans-3,4’,5-trihydroxystilbene; RSV) is a natural polyphenol 
compound found in peanuts, cranberries, and the skin of red grapes, and is thought to be 
one of the compounds responsible for the health benefits of moderate red wine consumption 
(184, 185).  The anti-inflammatory, anti-oxidant, cardioprotective, and antitumor properties 
of RSV have been well-documented in a variety of tissues (186-194), and recent studies have 
begun to analyze the effects of RSV on cartilage homeostasis. Elmali et al reported a 
significant protective effect of RSV injections on articular cartilage degradation in  rabbit 
models for OA and RA via histological analysis in vivo (195, 196).  In human articular 
chondrocytes, Shakibaei (197) and Czaki (198) have elucidated both anti-apoptotic and anti-
inflammatory regulatory mechanisms mediated by RSV.  In our laboratory, we have 
demonstrated potent anabolic and anti-catabolic potential of RSV in bovine spine nucleus 
pulposus IVD tissue (199) and human adult articular chondrocytes (Im et al., unpublished 
data) via inhibition of matrix-degrading enzyme expression at the transcriptional and 
translational level.  Further, combination therapy of RSV with BMP-7 induces synergistic 
effects on PG accumulation, and RSV reverses the catabolic effects of FGF-2 and IL-1 on 
matrix-degrading enzyme expression, PG accumulation, and the expression of factors 
(iNOS, IL-1, IL-6) associated with oxidative stress and inflammatory states (199).  Future 
studies are needed to assess the appropriate dose, route of administration, and downstream 
effects of RSV, as well as elucidate its role in old or degenerative cartilage in vivo.  
Nevertheless, these findings reveal considerable promise for use of RSV as a unique 
biological therapy for treatment of cartilage degenerative diseases in the future.  
4.3.5 Lactoferricin  
Bovine lactoferricin (LfcinB) is a 25-amino acid cationic peptide with an amphipatic, anti-
parallel ǃ-sheet structure that is obtained by acid-pepsin hydrolysis of the N-terminal region 
of lactoferrin (Lf) found in cow’s milk (200, 201). It exerts more potent biological effects than 
equimolar amounts of Lf, is cell membrane-permeable, and interacts electrostatically with 
negatively-charged matrix and cell surface glycosaminoglycans (GAGs), heparin and 
chondroitin sulfate (200, 201).  The anti-inflammatory, anti-viral, anti-bacterial, anti-oxidant, 
anti-pain, and anti-cancer properties of LfcinB have been reported in a variety of tissues 
(202, 203).  The natural anti-oxidative effect of LfcinB has also been reported, suggesting a 
possible chondroprotective biological role in articular cartilage (204), and several recent 
studies have attempted to elucidate the role of LfcinB in musculoskeletal disease.  In a 
mouse collagen-induced and septic arthritis model, periarticular injection of human Lf 
substantially suppresses local inflammation (205).  Further, in a rat adjuvant arthritis model, 
oral administration of bovine Lf suppresses the development of arthritis and hyperalgesia in 
the adjuvant-injected paw, suggesting Lf has preventative and therapeutic effects on the 
adjuvant-induced inflammation and pain (206). Human iron-free Lf delays the apoptosis of 
neutrophils isolated from synovial fluid of patients with established rheumatoid arthritis 
(207).  Lf was also identified as a novel bone growth factor, as local injection of Lf above the 
hemicalvaria of adult mice in vivo results in substantial increases in the dynamic 
histomorphometric indices of bone formation and bone area (208).  
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Previously in our laboratory, LfcinB was found to exert potent anabolic and anti-catabolic 
effects in bovine nucleus pulposus matrix homeostasis in the IVD, similar to RSV (209).  
Similar to the IVD, we also found similar anabolic and anti-catabolic effects of LfcinB in 
human articular cartilage (Im et al, unpublished data).  LfcinB reverses the catabolic effects 
of FGF-2 and IL-1 on matrix-degrading enzyme production, PG accumulation, and 
expression of factors associated with oxidative stress and inflammation, suggesting the 
promise of LfcinB as an anti-catabolic and anti-inflammatory molecule in human articular 
cartilage. Further, LfcinB abolishes the expression of iNOS, increases the expression of SOD-
1, and antagonizes the catabolic effects mediated by bFGF and IL-1 on iNOS and SOD-1 
expression, suggesting an anti-oxidative role of LfcinB in cartilage.   Taken together, much 
like RSV, LfcinB may play an important role in prevention and treatment of diseases such as 
OA.  Nevertheless, caution must be advised as further studies are warranted to determine, 
among other things, possible detrimental effects of its use in vivo.     
5. Pain modulators in OA 
Clinically, pain is the most prominent and disabling symptom of OA, and arthritic pain is 
associated with inferior functional outcomes and reduced quality of life compared with a 
range of other chronic conditions (210).  Like other chronic pain conditions, OA pain is a 
complex integration of sensory, affective and cognitive processes that involves a variety of 
abnormal cellular mechanisms at both peripheral (joints) and central (spinal and 
supraspinal) levels of the nervous system.  For the development of new therapies aimed at 
pain relief, a thorough understanding of the pathological mechanisms eliciting pain in OA is 
required.  Unfortunately, many of these mechanisms remain elusive because the primary 
site of pathology (i.e., articular cartilage) does not have neuronal pain receptors that can 
directly detect tissue injury due to mechanical damage.  The process by which painful 
mechanical stimuli from arthritic joints are converted into electrical signals that propagate 
along sensory nerves to the central nervous system remains to be fully explored. 
Nociceptors are located throughout the joint in tissues peripheral to cartilage, including the 
joint capsule, ligaments, periosteum and subchondral bone.  Joint cartilage and synovial 
injury influences peripheral afferent and dorsal root ganglion (DRG) neurons and sensitizes 
symptomatic pain perception through the dynamic interactions between neuropathic 
pathways and OA tissues.  Nociceptive input from the joint is processed via different spinal 
cord pathways, and inflammation may potentially reduce the threshold for pain.  The 
relative contribution of these processes into peripheral and central pathways appears to be 
strongly segmented (211), with intra-articular anesthetic studies in hip and knee OA 
suggesting a peripheral drive to pain in approximately 60% to 80% of patients, depending 
on the affected joint (212).  In some individuals, however, central mechanisms such as 
dysfunction of descending inhibitory control or altered cortical processing of noxious 
information, may play a greater role (213).  Therefore, research and pharmacotherapy for 
OA pain may be separated into two broad classes: central sensitization and peripheral 
sensitization, both leading to one final outcome: pain in a patient with OA.  
A detailed overview of the multiple, complex pathways associated with OA pain, 
particularly relating to central sensitization mechanisms, is outside the scope of this chapter.  
For example, current targets of pharmacotherapy for OA pain are numerous and include 
opioids, kinins, cannabinoids, and their respective receptors, in addition to adrenergic 
receptors, glutamate receptors, specific ion channels, and neurotrophins.  The literature is 
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replete with data on the alteration of pain pathways via inhibition of both central and 
peripheral processes (211).  Here, we will focus on select pro-inflammatory cytokines and 
mediators previously discussed in this chapter, and report their known roles in pain 
processing.  Our laboratory and others have mechanistically linked OA to pathological 
changes in the metabolism of ECM proteins and inflammatory states that may be controlled 
by epigenetic, epigenomic, and systemic processes involved in pain processing (5, 9, 89, 93, 
94, 199, 214, 215). 
5.1 Cytokines  
Inflammatory stimuli initiate a cascade of events, including the production of TNF-ǂ, 
interleukins, chemokines, sympathetic amines, substance P, leukotrienes and 
prostaglandins, each demonstrating a complex interplay with other mediators to induce 
pain (211, 216). Cytokines stimulate hyperalgesia by a number of direct and indirect actions.  
Sensitization of primary afferent fibers for mechanical stimuli is thought to be induced by 
inflammatory mediators.  IL-1ǃ activates nociceptors directly via intracellular kinase 
activation, but it may also induce indirect nociceptor sensitization via the production of 
kinins and prostanoids (217).   
IL-6, a well-known pro-inflammatory mediator, has been associated with hyperalgesia and 
hypersensitivity in articular cartilage (218).  As previously discussed, IL-6 plays an 
important role in the pathogenesis of rheumatoid arthritis, and its concentration is elevated 
in the serum and synovial fluid of arthritic patients (219, 220).  Interestingly, primary 
afferent neurons also respond to IL-6 (221), suggesting an important role of IL-6 in pain 
propagation in arthritic states.   
TNF-ǂ also activates sensory neurons directly via the receptors TNFR1 and TNFR2, and 
initiates a cascade of inflammatory reactions via the production of IL-1, IL-6 and IL-8 (217, 
222). Direct TNF-ǂ application in the periphery induces neuropathic pain, and this pain may 
be blocked by anti-inflammatory medications such as ibuprofen and celecoxib (223).  Anti-
TNF-ǂ treatment with a TNF antibody produces a prolonged reduction of pain symptoms in 
OA (224), and neutralization of TNF-ǂ in mice rescues both mechanical hyperalgesia (testing 
of withdrawal responses in behavioral experiments) and the inflammatory process (225).  
Taken together, TNF-ǂ induces an algesic effect, at least in part, via both neuronal and 
inflammatory stimulation. Antagonists to TNF-ǂ, such as etanercept or infliximab, may 
indeed serve as a potential therapeutic strategy to decrease OA pain clinically (211).  Further 
controlled studies are needed to substantiate these promising preliminary data on TNF 
inhibitors in OA.  
5.2 Prostanoids and PGE2 
During pro-inflammatory states, numerous prostanoid cyclooxygenase (COX) enzyme 
products are produced and released, including PGE2, PGD2, PGF2a, thromboxane, and 
PGI2 (211).  These factors serve as the premise for blocking the major synthetic enzymes 
COX-1 and COX-2 with selective or non-selective COX-inhibitor medications (ie. 
nonsteroidal anti-inflammatory drugs) (226).  Of these mediators, PGE2 is considered to be 
the major contributor to inflammatory pain in arthritic conditions. PGE2 exerts its effects via 
a variety of E prostanoid (EP) receptors (EP1, EP2, EP3, EP4), which are present in both 
peripheral sensory neurons and the spinal cord (211).  Activation of these receptors 
produces a variety of effects, ranging from calcium influx to cAMP activation or inhibition. 
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Peripherally, sensitization of nociceptors by PGE2 is caused by the cAMP-mediated 
enhancement of sodium currents after ion channel phosphorylation (227). However, in the 
spinal cord, PGE2 acts via different receptors than peripherally, suggesting further 
complexity in the prostanoid regulation of pain (228). 
In our laboratory, we have assessed the role of PGE2 in human adult articular cartilage 
homeostasis and its relation to possible pain pathways (58).  PGE2 utilizes the EP2 and EP4 
receptors downstream to induce its downstream catabolic effects, and PGE2 may mediate 
pain pathways in articular cartilage via its stimulatory effect on the pain-associated factors 
IL-6 (218) and iNOS (229).  Further, when combined with the catabolic cytokine IL-1, PGE2 
synergistically upregulates both IL-6 and iNOS mRNA levels in vitro (58).  Similar 
synergistic results were found with iNOS expression as well.  Therefore, the EP2/4 receptor 
may be an important signaling initiator of the PGE2-signaling cascade and a potential target 
for therapeutic strategies aimed at preventing progression of arthritic disease and pain in 
the future.   
As opposed to PGE2 EP receptor blockade, an alternative route of PGE2 inhibition is via the 
blockade of PGE synthase (PGES), a major route of conversion of prostaglandin H2 to PGE2 
(211). Two isoforms of the enzyme have been identified, membrane or microsomal 
associated (mPGES-1) and cytosolic (cPGES/p23), which are linked with COX-2 and COX-1 
dependent PGE2 production, respectively (230). Both isoforms are upregulated by 
inflammatory mediators, and gene deletion studies in mice indicate an important role for 
mPGES in acute and chronic inflammation and inflammatory pain, revealing a potential 
target for pain treatment in OA (211, 231).  
6. Discussion 
In summary, the literature reveals important roles of catabolic and anabolic growth factors 
and cytokines in articular cartilage homeostasis and the development of OA.  Each factor 
discussed plays a critical role in cartilage, both in normal homeostasis and in repair.  
Currently, many of these specific roles remain unknown, but recent efforts have begun to 
increase our understanding.  Catabolic factors include pro-inflammatory mediators (IL-1, IL-
6, IL-17, TNF-ǂ and PGE2), oxidative mediators (iNOS), glycoproteins (fibronectin, 
osteonectin, and osteopontin), and even growth factors (FGF-2).  In contrast, anabolic 
mediators include select interleukins, TGF-ǃ, IGF-1, BMPs (BMP-2 and BMP-7), RSV and 
LfcinB.  Upregulation of catabolic processes and/or downregulation of anabolic processes 
leads to disruption of equilibrium with subsequent cartilage degradation and OA, and 
several of these pathways are known to induce pain in OA as well (ie. IL-1, IL-6, NO, TNF-ǂ, 
PGE2).  The goal of biologic therapy is to retard this process via inhibition of catabolic 
processes and upregulation of anabolic processes with the hope of clinically preserving joint 
cartilage, thereby slowing or preventing the process of OA.   
Despite a tremendous research effort in recent years to elucidate these processes, however, 
biologic therapy for OA remains experimental in nature, and several unknowns exist.  Given 
the wide array of interactions of growth factors that are necessary for proper cartilage 
development and homeostasis in vivo, it is unlikely that any single growth factor will lead to 
complete cartilage repair or affect the arthritic joint clinically, and rather a combination 
approach will be required (149).  Further, appropriate dosing, scaffolds, and routes of 
administration must be determined before any of these factors plays a role clinically. 
Nevertheless, this chapter reviews several of the most well-studied biochemical mediators 
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involved in OA and provides a framework for the understanding of potential biologic 
therapies in the treatment of degenerative joint disease in the future.   
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